Preliminary Analysis of Data Evaluating Investigational Epco

02.06.2024 - Genmab A/S (Nasdaq: GMAB) today announced new efficacy and safety data from two ongoing Phase 1/2 clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in adult patients with certain types of ...

Related Keywords

Japan , Canada , Copenhagen , Køavn , Denmark , United States , America , Judith Klimovsky , Asia Pacific , Hematol Hemoter , Joshua Brody , Nasdaq , Linkedin , Lymphoma Research Foundation , Drug Administration , Genmab Us Inc , Data From The Observational National Lymphocare Study , Leukemia Lymphoma Society , Exchange Commission , Abbvie Biotechnology Ltd , Executive Vice President , Chief Development Officer , Mount Sinai Hess Center , Priority Review , Biologics License Application , Follicular Lymphoma , Medication Guide , North America , Media Release , Annual Report , Y Shaped Genmab , Abbvie Biotechnology , Opin Med , Accessed March , Subsequent Therapy , Data From , Observational National Lymphocare , Treatment Patterns , Patients With Diffuse Largeb Cell Lymphoma , Bras Hematol , Accessed February , Relapsed Follicular Lymphoma , Marginal Zone Lymphoma , Genmab Stock ,